Howard L Elford Selected Research

3,4-dihydroxybenzohydroxamic acid

1/2021	Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer.
1/2020	Didox (3,4-dihydroxybenzohydroxamic acid) reduces the vascular inflammation induced by acute intravascular hemolysis.
12/2017	Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IgE-mediated mast cell activation through attenuation of NFκB and AP-1 transcription.
11/2015	Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
1/2014	The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.
1/2011	Paradoxical response to prophylactic Didox (N-3, 4 trihydroxybenzamide) treatment in murine cytomegalovirus-infected mice.
1/2005	Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
8/2004	Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells.
6/2004	In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.
11/2002	Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Howard L Elford Research Topics

Disease

5	Neoplasms (Cancer) 01/2021 - 08/2002
5	Leukemia 01/2014 - 08/2002
3	Infections 01/2011 - 11/2002
3	Murine Acquired Immunodeficiency Syndrome (MAIDS) 01/2005 - 11/2002
2	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2015
2	Splenomegaly 06/2004 - 11/2002
2	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 06/2004 - 11/2002
1	Heart Failure 01/2021
1	Triple Negative Breast Neoplasms 01/2021
1	Left Ventricular Dysfunction 01/2021
1	Hemolysis 01/2020
1	Inflammation (Inflammations) 01/2020
1	Anaphylaxis (Anaphylactic Shock) 12/2017
1	Allergic Rhinitis 09/2017
1	Asthma (Bronchial Asthma) 09/2017
1	Atopic Dermatitis (Atopic Eczema) 09/2017
1	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2010
1	Atherosclerosis 12/2009
1	Coronary Artery Disease (Coronary Atherosclerosis) 12/2009
1	Vascular Remodeling 07/2005
1	Medulloblastoma 08/2004
1	Gliosarcoma 08/2004
1	Virus Diseases (Viral Diseases) 06/2004
1	Retroviridae Infections (Infection, Retrovirus) 11/2002
1	Disease Progression 11/2002
1	Prostatic Neoplasms (Prostate Cancer) 09/2002

Drug/Important Bio-Agent (IBA)

12	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2021 - 08/2002
11	3,4-dihydroxybenzohydroxamic acidIBA 01/2021 - 09/2002
5	Pharmaceutical PreparationsIBA 08/2010 - 11/2002
5	3,4,5-trihydroxybenzamidoximeIBA 02/2006 - 08/2002
3	Hydroxyurea (Hydrea)FDA LinkGeneric 07/2005 - 11/2002
3	AcidsIBA 06/2004 - 09/2002
2	Estrogen ReceptorsIBA 01/2021 - 11/2015
2	Immunoglobulin E (IgE)IBA 12/2017 - 09/2017
2	EnzymesIBA 07/2005 - 08/2002
2	DNA (Deoxyribonucleic Acid)IBA 06/2004 - 11/2002
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2004 - 08/2002
1	AnthracyclinesIBA 01/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	AntioxidantsIBA 12/2017
1	Interleukin-33IBA 09/2017
1	ribonucleotide reductase M2IBA 11/2015
1	Tamoxifen FDA LinkGeneric 11/2015
1	CytokinesIBA 01/2011
1	Gallic AcidIBA 01/2007
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2007
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2006
1	Cisplatin (Platino)FDA LinkGeneric 02/2006
1	Antiviral Agents (Antivirals)IBA 01/2005
1	Didanosine (Videx)FDA LinkGeneric 01/2005
1	Carmustine (FIVB)FDA Link 08/2004
1	Alkylating AgentsIBA 08/2004
1	GuanineIBA 06/2004
1	abacavir (Ziagen)FDA Link 06/2004
1	Antineoplastic Agents (Antineoplastics)IBA 01/2004
1	AmidoxIBA 01/2004
1	Free RadicalsIBA 11/2002
1	Radiation-Sensitizing AgentsIBA 09/2002
1	2'-deoxycytidine 5'-triphosphate (dCTP)IBA 08/2002

Therapy/Procedure

4	Therapeutics 01/2021 - 11/2002
2	Drug Therapy (Chemotherapy) 01/2004 - 08/2002
1	Adjuvant Chemotherapy 01/2021
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 08/2010
1	Stem Cell Transplantation 08/2010
1	Stents 12/2009